Published in Phys Rev Lett on November 08, 2010
Towards a scientific concept of free will as a biological trait: spontaneous actions and decision-making in invertebrates. Proc Biol Sci (2010) 1.45
Soliton-induced relativistic-scattering and amplification. Sci Rep (2012) 0.88
Rogue events in the group velocity horizon. Sci Rep (2012) 0.86
Taming the collapse of optical fields. Sci Rep (2012) 0.80
On cosmology in the laboratory. Philos Trans A Math Phys Eng Sci (2015) 0.80
Comment on "Hawking radiation from ultrashort laser pulse filaments". Phys Rev Lett (2011) 0.79
Optical analogues of the Newton-Schrödinger equation and boson star evolution. Nat Commun (2016) 0.75
Analogue Gravity. Living Rev Relativ (2011) 0.75
Optical Dark Rogue Wave. Sci Rep (2016) 0.75
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev (1992) 3.30
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
The checkpoint protein Ddc2, functionally related to S. pombe Rad26, interacts with Mec1 and is regulated by Mec1-dependent phosphorylation in budding yeast. Genes Dev (2000) 2.82
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 2.77
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
Early T-helper cell defects in HIV infection. AIDS (1991) 1.93
Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol (1996) 1.93
HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS (1999) 1.89
Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis (1999) 1.88
Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS (1998) 1.86
Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol (1993) 1.84
Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest (1989) 1.77
Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today (1996) 1.75
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol (2000) 1.69
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis (1995) 1.69
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS (2000) 1.66
Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 1.65
Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation. Neurology (2010) 1.59
Alloimmunization as an AIDS vaccine? Science (1993) 1.58
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54
Characterization of mec1 kinase-deficient mutants and of new hypomorphic mec1 alleles impairing subsets of the DNA damage response pathway. Mol Cell Biol (2001) 1.53
Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy. Lancet (1998) 1.50
Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest (1991) 1.44
In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis (1996) 1.41
Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J Pediatr (1999) 1.41
Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res (1996) 1.39
Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS (1996) 1.39
A strategy for prophylactic vaccination against HIV. Science (1993) 1.38
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 1.36
Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis (1996) 1.36
CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin Exp Immunol (1996) 1.35
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett (2001) 1.31
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol (2011) 1.30
CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol (2000) 1.28
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.28
Polariton superfluids reveal quantum hydrodynamic solitons. Science (2011) 1.26
Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol (1993) 1.25
Prevalence and clinical presentation of subclinical/silent celiac disease in adults: an analysis on a 12-year observation. Hepatogastroenterology (2001) 1.25
T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS (2001) 1.23
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost (2009) 1.19
Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS (2001) 1.16
Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori (1982) 1.16
Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol (1995) 1.11
Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect Dis (2000) 1.09
PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiol Aging (2005) 1.09
The PD-1/PD-L1 pathway in human pathology. Curr Mol Med (2012) 1.08
Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS (2000) 1.07
Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. J Immunol (1994) 1.05
Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect (2000) 1.04
Unusual malignant tumours in 49 patients with HIV infection. AIDS (1989) 1.04
Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell counts. J Infect Dis (1991) 1.04
Genetic correlates of protection against HIV infection: the ally within. J Intern Med (2009) 1.04
Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol (2001) 1.04
Human in vitro allogeneic responses. Demonstration of three pathways of T helper cell activation. J Immunol (1990) 1.03
Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. J Pediatr (1995) 1.03
T cell-antigen-presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects. J Immunol (1993) 1.02
Survival after trochanteric fracture. Biological factors analyzed in 270 patients. Acta Orthop Scand (1992) 1.01
Insulin sensitivity is impaired in patients with migraine. Cephalalgia (2005) 1.01
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol (2011) 1.00
Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. J Immunol (1995) 1.00
Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS (1996) 0.99
Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst (1998) 0.98
BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur J Neurol (2009) 0.98
A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. Neurology (2004) 0.98
HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. J Biol Regul Homeost Agents (2000) 0.97
Negative-frequency resonant radiation. Phys Rev Lett (2012) 0.97
Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission. Clin Exp Immunol (2001) 0.96
T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation. Chem Immunol (1992) 0.96
Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer (1996) 0.96
Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut (2007) 0.95
Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int J Immunopathol Pharmacol (2009) 0.95
Correlation of in vitro CD4+ T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. Transplantation (1991) 0.95
Road traffic accidents with vehicular entrapment: incidence of major injuries and need for advanced life support. Eur J Emerg Med (1999) 0.94
The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clin Infect Dis (2013) 0.94
Long-term balancing selection maintains trans-specific polymorphisms in the human TRIM5 gene. Hum Genet (2010) 0.93
Myositis ossificans traumatica of the temporal muscle: a case report. Auris Nasus Larynx (2001) 0.93
The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst (1996) 0.93
Expressed emotion and schizophrenia in Italy. A study of an urban population. Br J Psychiatry (1992) 0.93
Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun (2001) 0.93
Cytokine profiles in HIV type 1 disease and protection. AIDS Res Hum Retroviruses (1998) 0.92
Helper T-cell responses in children infected with human immunodeficiency virus type 1. J Pediatr (1991) 0.92
HIV-1 antibody serum negativity with urine positivity. Lancet (1993) 0.91
Retinoids: in vitro interaction with retinol-binding protein and influence on plasma retinol. FASEB J (1993) 0.91
Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry (1998) 0.91
International collaborative study for the calibration of a proposed reference preparation for thromboplastin, human recombinant, plain. On behalf of the Subcommittee on Control of Anticoagulation. Thromb Haemost (1998) 0.91
Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease. Acta Neurol Scand (2013) 0.91
Mannanoligosaccharides and aflatoxin B1 in feed for laying hens: effects on egg quality, aflatoxins B1 and M1 residues in eggs, and aflatoxin B1 levels in liver. Poult Sci (2005) 0.91
Carbon emissions. The economic benefits of the Kyoto Protocol. Nature (2001) 0.90
Type 1 and type 2 cytokines in HIV infection -- a possible role in apoptosis and disease progression. Ann Med (1997) 0.90
Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. AIDS (1996) 0.90
Glucocorticoids and Th-1, Th-2 type cytokines in rheumatoid arthritis, osteoarthritis, asthma, atopic dermatitis and AIDS. Clin Exp Rheumatol (1997) 0.90
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. Eur J Neurol (2013) 0.90
Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor alpha. AIDS Res Hum Retroviruses (1998) 0.89
Assessing cell trafficking by noninvasive imaging techniques: applications in experimental tumor immunology. Q J Nucl Med Mol Imaging (2005) 0.89
Brucella abortus stimulates human T cells from uninfected and HIV-infected individuals to secrete IFN gamma: implications for use of Brucella abortus as a carrier in development of human vaccines. AIDS Res Hum Retroviruses (1992) 0.89
A partial factor V deficiency in anticoagulated lyophilized plasmas has been identified as a cause of the international normalized ratio discrepancy in the external quality assessment scheme. Thromb Res (1995) 0.89